1. Home
  2. SACH vs CTSO Comparison

SACH vs CTSO Comparison

Compare SACH & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.03

Market Cap

49.6M

Sector

Real Estate

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.63

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
CTSO
Founded
2010
1997
Country
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.6M
45.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SACH
CTSO
Price
$1.03
$0.63
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$2.00
$5.38
AVG Volume (30 Days)
127.1K
79.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
19.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$7.29
Revenue Next Year
$1.73
$8.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.60
52 Week High
$1.35
$1.39

Technical Indicators

Market Signals
Indicator
SACH
CTSO
Relative Strength Index (RSI) 47.23 42.55
Support Level $0.99 $0.62
Resistance Level $1.06 $0.67
Average True Range (ATR) 0.03 0.05
MACD -0.00 -0.00
Stochastic Oscillator 43.75 6.82

Price Performance

Historical Comparison
SACH
CTSO

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: